Main content

Combined treatment of canine osteosarcoma cells with gene knock-down and chemotherapy

Show simple item record

dc.contributor.advisor Wood, Geoffrey
dc.contributor.author Gallienne, Jacqueline
dc.date.accessioned 2014-08-29T13:12:54Z
dc.date.available 2014-08-29T13:12:54Z
dc.date.copyright 2014-08
dc.date.created 2014-08-25
dc.date.issued 2014-08-29
dc.identifier.uri http://hdl.handle.net/10214/8351
dc.description.abstract Companion animals, such as the dog, can spontaneously develop cancers just like humans. Canine osteosarcoma (OSA) is a highly aggressive type of bone cancer that shares striking disease similarities with human OSA, including molecular aberrations to the R1 alpha regulatory subunit of cyclic AMP-dependent protein kinase A, or PRKAR1A. Low PRKAR1A-expressing tumours are associated with the best post-chemotherapy response in human OSA patients, and similarly, canine patients with low PRKAR1a protein expression in their primary tumours lived significantly longer post-chemotherapy treatment compared to dogs with high PRKAR1a-expressing tumours. Knowing this, we sought to investigate the in vitro effects of gene knock-down in canine OSA cells using small interfering RNAs (siRNAs) directed against PRKAR1A mRNA transcripts. Here, we hypothesized that PRKAR1a knock-down would enhance sensitivity to conventional chemotherapeutic drugs, including doxorubicin and carboplatin. The present study included four canine OSA cell lines, one commercially available D17 cell line and three primary cell lines, each with different endogenous PRKAR1a protein expression levels. Our findings show that PRKAR1a knock-down as a treatment alone reduced cellular viability and increased apoptosis in some canine OSA cell lines, although no gross changes were detected in soft agar growth. Interestingly, pretreatment with PRKAR1A siRNAs enhanced chemosensitivity to doxorubicin in some canine OSA cell lines; however no significant benefit was detected if PRKAR1A silencing was combined with carboplatin chemotherapy. Overall, this study prompts further investigation into PRKAR1a as a potential therapeutic target to sensitize bone cancer cells to chemotherapy, leading to enhanced treatment efficacy and improved patient survival for both humans and dogs. en_US
dc.language.iso en en_US
dc.subject Osteosarcoma en_US
dc.title Combined treatment of canine osteosarcoma cells with gene knock-down and chemotherapy en_US
dc.type Thesis en_US
dc.degree.programme Pathobiology en_US
dc.degree.name Master of Science en_US
dc.degree.department Department of Pathobiology en_US


Files in this item

Files Size Format View
Gallienne_Jacqueline_201408_MSc.pdf 2.090Mb PDF View/Open

This item appears in the following Collection(s)

Show simple item record